Auron Therapeutics
PrivateLast Round
Seed Round
Aug 10, 2026
Est. Valuation
$158M
Total Funding Raised
$87.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Auron Therapeutics operates in Healthcare & Life Sciences and is based in Newton, Massachusetts. Its latest recorded funding round was a Series B round in February 2025.
Auron Therapeutics is a biotechnology company that develops targeted small molecule therapies by analyzing dysfunctional cell states to treat cancers and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Auron Therapeutics Comparables
Compare Auron Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Monte Rosa Therapeutics | 81% | |
| Accent Therapeutics | 81% | |
| C4 Therapeutics | 80% |
For institutional investors. Book with your work email.
Auron Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Aug 10, 2026 | ||||
| Series B | Feb 4, 2025 | ||||
| Series A | Jul 20, 2022 | ||||
| Seed | Jan 27, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Auron Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apollo Ventures | Series B, Series A |
| DCVC Bio | Series B, Series A |
| BrightEdge | Series B, Series A, Seed |
| BrightEdge | Series B, Series A, Seed |
| Arkin Holdings | Series B, Series A |
| Mubadala Capital | Series B, Series A |
| Qiming | Series B, Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 60% MoM.
- Aug 10, 2026
Raised $7.1M in Seed funding.
For institutional investors. Book with your work email.
Auron Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Auron Therapeutics's valuation, stock price, and market status.
Is Auron Therapeutics a public or private company?
Auron Therapeutics is a private company.
What is the current stock price of Auron Therapeutics?
Auron Therapeutics is a private company, so its shares have no public market price. Caplight tracks Auron Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Auron Therapeutics worth (valuation)?
Auron Therapeutics's valuation is estimated at $158.0M based on funding round data.
Can I buy Auron Therapeutics stock?
Auron Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Auron Therapeutics's last funding round?
Auron Therapeutics's most recent funding round was Seed Round on August 10, 2026.
Who are the main investors in Auron Therapeutics?
Key investors in Auron Therapeutics include DCVC Bio, Qiming, Polaris Partners, Arkin Bio Ventures, Creyon Bio.
Will Auron Therapeutics IPO soon?
No public IPO plans have been announced for Auron Therapeutics.
How can I track Auron Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Auron Therapeutics's shares on secondary markets.